Endothelial glycocalyx degradation in multisystem inflammatory syndrome in children related to COVID-19

Noemi Veraldi1, Romain R Vivès2, Géraldine Blanchard-Rohner3,4

  • 1Department of Diagnostics, Division of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland.

Journal of Molecular Medicine (Berlin, Germany)
|March 29, 2022
PubMed

Insights

Multisystem inflammatory syndrome in children (MIS-C) involves endothelial glycocalyx injury, indicated by elevated syndecan-1 and heparan sulfate. These markers correlate with disease severity and may predict complications in COVID-19 patients.

Area of Science:

  • Pediatric critical care medicine
  • Infectious diseases
  • Vascular biology

Background:

  • Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection.
  • Endothelial dysfunction is implicated in COVID-19, but its role in MIS-C requires further characterization.
  • The endothelial glycocalyx, a protective vascular lining, may be affected in MIS-C.

Purpose of the Study:

  • To investigate endothelial glycocalyx degradation in children diagnosed with MIS-C.
  • To correlate glycocalyx markers with clinical severity and inflammatory markers.
  • To explore potential biomarker utility for MIS-C and severe COVID-19.

Main Methods:

  • Blood and urine samples were collected from 17 MIS-C patients and 5 healthy controls.
  • Proinflammatory cytokines, myocardial injury markers, and endothelial glycocalyx markers were measured.
  • Levels of syndecan-1, heparan sulfate, and chondroitin sulfate were analyzed.

Main Results:

  • All MIS-C patients exhibited signs of glycocalyx deterioration.
  • Elevated blood syndecan-1 and urinary heparan sulfate/chondroitin sulfate were observed in MIS-C patients.
  • The extent of glycocalyx shedding correlated with tumor necrosis factor-alpha levels and disease severity.

Conclusions:

  • Children with MIS-C show significant endothelial glycocalyx injury.
  • Syndecan-1 and heparan sulfate may serve as potential biomarkers for MIS-C severity.
  • Further research is needed to validate these biomarkers for predicting complications in MIS-C and severe COVID-19.

Related Concept Videos